Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
5.74
0.00 (0.00%)
Mar 9, 2026, 2:57 PM EDT - Market open
Artiva Biotherapeutics Employees
Artiva Biotherapeutics had 89 employees as of December 31, 2024. The number of employees increased by 46 or 106.98% compared to the previous year.
Employees
89
Change
46
Growth
106.98%
Revenue / Employee
n/a
Profits / Employee
-$747,057
Market Cap
140.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89 | 46 | 106.98% |
| Dec 31, 2021 | 43 | 21 | 95.45% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Zentalis Pharmaceuticals | 166 |
| Adagene | 138 |
| Connect Biopharma Holdings | 62 |
| Spero Therapeutics | 32 |
| Corbus Pharmaceuticals Holdings | 28 |
ARTV News
- 12 days ago - Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 13 days ago - Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - GlobeNewsWire
- 18 days ago - Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - GlobeNewsWire
- 6 weeks ago - Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - GlobeNewsWire
- 7 weeks ago - Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored - Seeking Alpha
- 4 months ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - GlobeNewsWire